|
|
 Previous Article | Table of Contents | Next Article 
Serum CD44 in malignant lymphoma: an association with treatment response
R Ristamaki, H Joensuu, M Salmi and S Jalkanen
National Public Health Institute, Turku, Finland.
CD44, a cell surface glycoprotein, is involved in lymphocyte trafficking
from the blood to lymphatic tissues, and is of importance in dissemination
of lymphoma. A variant form of CD44 that has additional amino acids in the
common protein backbone (CD44v6) also seems to play a role in the
metastatic dissemination of malignancies. We measured serum CD44 and CD44v6
in 34 patients with lymphoma and in healthy controls by dot blot assay.
Small amounts of both CD44 (range, 10 to 80 ng/mL) and CD44v6 could be
detected in sera of all controls. Serum CD44 was elevated in all patients
with lymphoma before treatment (range, 70 to > 2,000 ng/mL, P <
.0001), and CD44v6 was also slightly elevated. Serum CD44 levels correlated
with response to treatment. Patients with complete response achieved
similar CD44 levels as the controls, whereas those with progressive disease
had increased serum CD44 levels. We conclude that both the standard and the
variant form of CD44 are detectable in sera of healthy individuals, and
that serum CD44 may be useful in monitoring treatment response in patients
with lymphoma.
Volume 84,
Issue 1,
pp. 238-243,
07/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. W. Van Hal, G. A. M. S. Van Dongen, C. B. M. Ten Brink, K.-H. Heider, I. Rech-Weichselbraun, G. B. Snow, and R. H. Brakenhoff
Evaluation of Soluble CD44v6 as a Potential Serum Marker for Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res.,
November 1, 1999;
5(11):
3534 - 3541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W Reinisch, K-H Heider, G Oberhuber, C Dejaco, M Mullner, G R Adolf, and C Gasche
Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease
Gut,
September 1, 1998;
43(3):
375 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurkijarvi, D. H. Adams, R. Leino, T. Mottonen, S. Jalkanen, and M. Salmi
Circulating Form of Human Vascular Adhesion Protein-1 (VAP-1): Increased Serum Levels in Inflammatory Liver Diseases
J. Immunol.,
August 1, 1998;
161(3):
1549 - 1557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ristamaki, H. Joensuu, K. Lappalainen, L. Teerenhovi, and S. Jalkanen
Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma
Blood,
November 15, 1997;
90(10):
4039 - 4045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Airas, J. Niemela, M. Salmi, T. Puurunen, D. J. Smith, and S. Jalkanen
Differential Regulation and Function of CD73, a Glycosyl-Phosphatidylinositol-linked 70-kD Adhesion Molecule, on Lymphocytes and Endothelial Cells
J. Cell Biol.,
January 27, 1997;
136(2):
421 - 431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yu and B. P. Toole
A New Alternatively Spliced Exon between v9 and v10 Provides a Molecular Basis for Synthesis of Soluble CD44
J. Biol. Chem.,
August 23, 1996;
271(34):
20603 - 20607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
